Company Description
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States.
Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial.
In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma.
Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jun 15, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Ted White |
Contact Details
Address: 10 North High Street, Suite 200 West Chester, Pennsylvania 19380 United States | |
| Phone | 484-453-3300 |
| Website | verrica.com |
Stock Details
| Ticker Symbol | VRCA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001660334 |
| CUSIP Number | 92511W108 |
| ISIN Number | US92511W1080 |
| Employer ID | 46-3137900 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ted White | President, Chief Executive Officer and Director |
| Joe Bonaccorso | Chief Commercial Officer |
| Dr. Gary Goldenberg M.D. | Chief Medical Officer |
| P. Terence Kohler | Chief Financial Officer |
| Christopher G. Hayes | Chief Legal Officer, Secretary, Chief Compliance Officer and General Counsel |
| Eugene Scavola | Executive Vice President of Technical Operations |
| Dr. Bradley J. Catalone MBA, Ph.D. | Head of Drug Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | 8-K | Current Report |
| Jun 10, 2024 | 8-K | Current Report |
| May 15, 2024 | 8-K | Current Report |
| May 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 19, 2024 | ARS | Filing |
| Apr 19, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 19, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 29, 2024 | 10-K | Annual Report |